Gary M. Owens, MD

Specialty pharmaceuticals are currently the object of payer focus as one of the major drivers of increased pharmacy spending in 2014 and beyond.

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.